Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer

Erin R. Gaddes, Deborah Lee, Gregory Gydush, Yong Wang, Cheng Dong

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Molecular intervention during transient stages of various metastatic pathways may lead to development of promising therapeutic technologies. One of such involves soluble fibrin (sFn) that has been implicated as a cross-linker between circulating blood or tumor cells and endothelial cell receptors, promoting cell arrest on the endothelium during circulation. sFn generation is a result of thrombin-mediated fibrinogen (Fg) cleavage due to either vascular injuries or a tumor microenvironment. For cancer therapy, thrombin-mediated conversions of Fg to sFn thus serve as potential intervention points to decrease circulating tumor cell adhesion to the endothelium and subsequent metastatic events. The purpose of this work was to investigate the function of an anti-thrombin oligonucleotide aptamer in reducing tumor cell arrest. Both molecular and cellular interactions were examined to demonstrate the binding and inhibitory effects of anti-thrombin aptamer. The results show that the aptamer is capable of inhibiting thrombin-mediated Fg conversion, thereby reducing sFn-mediated tumor cell adhesion in a concentration-dependent manner. Notably, the aptamer is able to bind thrombin under dynamic flow conditions and reduce tumor cell adhesive events at various physiological shear rates. This study further indicates that oligonucleotide aptamers hold great promise as therapeutic regulators of tumor cell adhesion, and consequently, metastatic activity.

Original languageEnglish (US)
Pages (from-to)417-426
Number of pages10
JournalExperimental Cell Research
Volume339
Issue number2
DOIs
StatePublished - Dec 1 2015

Fingerprint

Fibrin
Cell Adhesion
Endothelium
Thrombin
Fibrinogen
Neoplasms
Oligonucleotides
Circulating Neoplastic Cells
Tumor Microenvironment
Vascular System Injuries
Adhesives
thrombin aptamer
Therapeutics
Endothelial Cells
Technology

All Science Journal Classification (ASJC) codes

  • Cell Biology

Cite this

@article{c814f5ac2c5f47d4bebeaca48afbd435,
title = "Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer",
abstract = "Molecular intervention during transient stages of various metastatic pathways may lead to development of promising therapeutic technologies. One of such involves soluble fibrin (sFn) that has been implicated as a cross-linker between circulating blood or tumor cells and endothelial cell receptors, promoting cell arrest on the endothelium during circulation. sFn generation is a result of thrombin-mediated fibrinogen (Fg) cleavage due to either vascular injuries or a tumor microenvironment. For cancer therapy, thrombin-mediated conversions of Fg to sFn thus serve as potential intervention points to decrease circulating tumor cell adhesion to the endothelium and subsequent metastatic events. The purpose of this work was to investigate the function of an anti-thrombin oligonucleotide aptamer in reducing tumor cell arrest. Both molecular and cellular interactions were examined to demonstrate the binding and inhibitory effects of anti-thrombin aptamer. The results show that the aptamer is capable of inhibiting thrombin-mediated Fg conversion, thereby reducing sFn-mediated tumor cell adhesion in a concentration-dependent manner. Notably, the aptamer is able to bind thrombin under dynamic flow conditions and reduce tumor cell adhesive events at various physiological shear rates. This study further indicates that oligonucleotide aptamers hold great promise as therapeutic regulators of tumor cell adhesion, and consequently, metastatic activity.",
author = "Gaddes, {Erin R.} and Deborah Lee and Gregory Gydush and Yong Wang and Cheng Dong",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.yexcr.2015.10.010",
language = "English (US)",
volume = "339",
pages = "417--426",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "2",

}

Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer. / Gaddes, Erin R.; Lee, Deborah; Gydush, Gregory; Wang, Yong; Dong, Cheng.

In: Experimental Cell Research, Vol. 339, No. 2, 01.12.2015, p. 417-426.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulation of fibrin-mediated tumor cell adhesion to the endothelium using anti-thrombin aptamer

AU - Gaddes, Erin R.

AU - Lee, Deborah

AU - Gydush, Gregory

AU - Wang, Yong

AU - Dong, Cheng

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Molecular intervention during transient stages of various metastatic pathways may lead to development of promising therapeutic technologies. One of such involves soluble fibrin (sFn) that has been implicated as a cross-linker between circulating blood or tumor cells and endothelial cell receptors, promoting cell arrest on the endothelium during circulation. sFn generation is a result of thrombin-mediated fibrinogen (Fg) cleavage due to either vascular injuries or a tumor microenvironment. For cancer therapy, thrombin-mediated conversions of Fg to sFn thus serve as potential intervention points to decrease circulating tumor cell adhesion to the endothelium and subsequent metastatic events. The purpose of this work was to investigate the function of an anti-thrombin oligonucleotide aptamer in reducing tumor cell arrest. Both molecular and cellular interactions were examined to demonstrate the binding and inhibitory effects of anti-thrombin aptamer. The results show that the aptamer is capable of inhibiting thrombin-mediated Fg conversion, thereby reducing sFn-mediated tumor cell adhesion in a concentration-dependent manner. Notably, the aptamer is able to bind thrombin under dynamic flow conditions and reduce tumor cell adhesive events at various physiological shear rates. This study further indicates that oligonucleotide aptamers hold great promise as therapeutic regulators of tumor cell adhesion, and consequently, metastatic activity.

AB - Molecular intervention during transient stages of various metastatic pathways may lead to development of promising therapeutic technologies. One of such involves soluble fibrin (sFn) that has been implicated as a cross-linker between circulating blood or tumor cells and endothelial cell receptors, promoting cell arrest on the endothelium during circulation. sFn generation is a result of thrombin-mediated fibrinogen (Fg) cleavage due to either vascular injuries or a tumor microenvironment. For cancer therapy, thrombin-mediated conversions of Fg to sFn thus serve as potential intervention points to decrease circulating tumor cell adhesion to the endothelium and subsequent metastatic events. The purpose of this work was to investigate the function of an anti-thrombin oligonucleotide aptamer in reducing tumor cell arrest. Both molecular and cellular interactions were examined to demonstrate the binding and inhibitory effects of anti-thrombin aptamer. The results show that the aptamer is capable of inhibiting thrombin-mediated Fg conversion, thereby reducing sFn-mediated tumor cell adhesion in a concentration-dependent manner. Notably, the aptamer is able to bind thrombin under dynamic flow conditions and reduce tumor cell adhesive events at various physiological shear rates. This study further indicates that oligonucleotide aptamers hold great promise as therapeutic regulators of tumor cell adhesion, and consequently, metastatic activity.

UR - http://www.scopus.com/inward/record.url?scp=84951036738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951036738&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2015.10.010

DO - 10.1016/j.yexcr.2015.10.010

M3 - Article

C2 - 26481421

AN - SCOPUS:84951036738

VL - 339

SP - 417

EP - 426

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 2

ER -